# Roche CDR (CAD Hedged) (ROG.TO) fundamentals

Data as of 2026-11-04. TSX, Canada. Sector: Healthcare / Pharmaceuticals. Price C$31.21, market value C$499.8 billion.

## Valuation
- **P/E (trailing): 23.5×** (5-yr avg 31.7×, 3-yr avg 31.7×). Roche CDR (CAD Hedged) trades at 23.5× trailing earnings, well below its own five-year average of 31.7×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×.
- **Price / sales: 7.9×**. Each dollar of revenue is priced at 7.9×.
- **Price / book: 3.6×**. The shares trade at 3.6× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 23.8×**. Enterprise value is 23.8× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 2.6%** (5-yr avg 3.2%). Free cash flow equals 2.6% of the market value, in line with its five-year average of 3.2%.
- **Earnings yield: 4.3%**. The inverse of the P/E: 4.3% of the price is earned each year.

## Profitability
- **Gross margin: 73.7%**. Roche CDR (CAD Hedged) keeps 73.7% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 29.2%**. 29.2% of revenue is left after running the business, an exceptional level.
- **Net margin: 20.3%**. 20.3% of each dollar of sales reaches the bottom line.
- **Return on equity: 38.1%**. 38.1% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on invested capital: 29.2%**. Return on all capital, debt included, is 29.2%: comfortably above what that capital costs.
- **Return on assets: 12.8%**. Each dollar of assets produces 12.8% of profit.

## Growth
- **Revenue growth (1 yr): 1.5%** (3-yr -1.3%/yr). Revenue grew 1.5% over the last year.
- **EPS growth (1 yr): 55.6%** (3-yr 1.4%/yr). Earnings per share rose 55.6%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): -0.4%/yr**. Free cash flow has compounded at -0.4% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.98**. Debt is 0.98 times equity, moderate leverage.
- **Net debt / EBITDA: 0.8×**. It would take 0.8 years of operating earnings to repay net borrowings, within the comfortable range.
- **Interest coverage: 13.7×**. Operating profit covers interest 13.7× over, a safe margin.
- **Current ratio: 1.38** (quick 1.12). Current assets cover the next year's liabilities 1.38 times.
- **Altman Z-score: 6.74**. A Z-score of 6.74 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 6/9**. 6 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Roche CDR (CAD Hedged) does not currently pay a dividend, but it returned 0.2% of its market value through buybacks over the last year.

## Price and momentum
- **Total return (1 yr): 59.0%** (YTD 26.5%, 3-mo 13.7%). The shares are up 59.0% over twelve months including dividends.
- **From 52-week high: -2.7%** (50.2% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 75**. An RSI of 75 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.31** (volatility 25%). Beta of 0.31 against the S&P/TSX Composite: the shares move much less than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=ROG.TO · Page: https://foliofundamentals.com/stocks/rog.to

Not investment advice.